Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyIndependent Health OIT Coverage Policy Update | Op…
    Ask Trek AI about this page
    CurrentIndependent HealthPolicy M20201217222

    Oral Immunotherapy (OIT) for the Treatment of Food Allergy

    Customize your policy alerts

    Sign up for Independent Health Policy M20201217222 alerts

    Get alerted when Policy M20201217222 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Independent Health's medical necessity criteria for oral immunotherapy for food allergy across applicable lines of business (commercial, Medicare Advantage, MediSource/State products). It specifies coverage when FDA-approved therapy is used and treats other OIT as investigational.

    Policy Summary
    PayerIndependent Health
    PolicyOral Immunotherapy (OIT) for the Treatment of Food Allergy
    Policy CodePolicy M20201217222
    Change TypeNo material change
    Effective DateFeb 2, 2021
    Last ReviewJan 1, 2025
    Next Review Date
    Key ActionNo pre-authorization is required at present; apply criteria on retrospective review and limit coverage to FDA‑approved OIT (currently Palforzia for peanut).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1FDA-approved OIT product specified
    1 per allergenChallenge tests per allergen

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    NoPre-auth stance
    NYApplies to

    Medical Necessity and Investigational Determinations

    Medical Necessity and Investigational Determinations

    Covered when ALL of the following are met for Commercial and Self‑Funded; Medicare Advantage uses the same criteria; State products follow New York–specific rules for challenge testing:

    Primary coverage condition: Oral immunotherapy is considered medically necessary when delivered with a Food and Drug Administration (FDA)–approved therapy (currently Palforzia for peanut).

    Refer to Independent Health Pharmacy policy M20200227015 for Palforzia criteria.

    Investigational / Not covered: Oral immunotherapy is considered experimental/investigational under any other circumstances (i.e., OIT delivered with non–FDA–approved products or protocols).

    Requests for non‑FDA OIT would be denied as investigational due to lack of published scientific evidence.

    Food challenge testing: Food challenge tests are covered once per suspected food allergen.1 per allergen

    Any requests for additional challenges for the same food require authorization from an Independent Health Medical Director and must include specific clinical documentation supporting the need for repeat testing.

    NY State (MediSource, Child Health Plus, Essential Plan) rules: Oral ingestion challenge testing should not be used as first‑line testing and must be performed in a carefully supervised allergy specialist setting with emergency support immediately available; it may be medically necessary when in vivo/in vitro testing is inconclusive or inconsistent with clinical symptoms.

    Indications include confirming a positive in vivo/in vitro test or testing for allergic response to foods/ingested substances or oral medications when specific conditions are met.

    Any oral immunotherapy (OIT) that is not delivered with an FDA‑approved therapy is considered experimental/investigational and is excluded from coverage.

    Oral immunotherapy approaches that do not use an FDA‑approved product (for example, other desensitization protocols or non‑approved OIT preparations) are considered investigational and therefore not medically necessary.

    Provider Requirements and Authorization

    Prior Authorization

    No pre-authorization required; coverage limited to FDA‑approved OIT

    Pre-authorization is not required at the present time; the policy criteria will be applied on retrospective review. Coverage is limited to oral immunotherapy when delivered with an FDA‑approved therapy (currently Palforzia for peanut).

    Step Therapy

    Challenge testing must be specialist‑supervised and not first‑line

    Per New York State criteria, oral ingestion challenge testing should not be used as first-line testing and must be performed only in a carefully supervised allergy specialist setting with emergency support immediately available.

    • Oral ingestion challenge testing may be medically necessary when in vivo/in vitro testing is inconclusive or inconsistent with clinical symptoms.
    • For oral medications, challenge testing is allowed only when patient has a history of allergy to the drug, no effective alternative exists, and the patient requires treatment with the drug class.

    Clinical Background

    The current standard of care for food allergy is avoidance of the allergen and treatment of anaphylaxis with auto‑injectable epinephrine. The therapeutic goal is induction of permanent tolerance so the food can be consumed without recurrent reactions; however, current evidence indicates that OIT is unlikely to induce permanent tolerance.

    Key Definitions

    Desensitization — definition entry
    DefinitionDesensitization: improvement in food challenge outcomes after therapy that relies on ongoing exposure to the allergen.
    ContextDesensitization describes a temporary increase in reaction threshold that depends on continued exposure to the allergen.
    Relation to OITOften used to describe outcomes of oral immunotherapy where maintenance exposure is required to preserve benefit.
    Oral immunotherapy (OIT) — definition entry
    DefinitionOral immunotherapy (OIT): feeding an allergic individual an increasing amount of an allergen with the goal of increasing the threshold that triggers a reaction.
    Therapeutic goalRaise the reaction threshold to reduce risk from accidental exposures rather than necessarily inducing permanent tolerance.
    Policy Summary
    PayerIndependent Health
    PolicyOral Immunotherapy (OIT) for the Treatment of Food Allergy
    Policy CodePolicy M20201217222
    Change TypeNo material change
    Effective DateFeb 2, 2021
    Last ReviewJan 1, 2025
    Next Review Date
    Key ActionNo pre-authorization is required at present; apply criteria on retrospective review and limit coverage to FDA‑approved OIT (currently Palforzia for peanut).
    SourceLink
    On This Page
    Medical Necessity and Investigational DeterminationsProvider Requirements and AuthorizationClinical BackgroundKey Definitions
    Documentation Required

    Document complete exam, history, and retain records (≥6 years)

    A complete physical exam and a detailed review of the patient’s clinical history must be documented prior to performing allergy testing; the ordering physician must maintain sufficient documentation to support medical necessity and retain medical records for at least six years from the date of payment.

    • Testing should be performed only by licensed physicians who can interpret results, manage adverse reactions, and determine treatment.
    • Providers are responsible for appropriate billing and should expect possible retrospective reviews by Medicaid utilization contractors or the Office of the Medicaid Inspector General.
    Denial Risk

    Non‑FDA OIT is investigational — risk of denial

    Oral immunotherapy is considered experimental/investigational under any circumstances other than when delivered with an FDA‑approved therapy (Palforzia for peanut); requests for non‑FDA OIT would be denied as investigational.

    • Any OIT not delivered with an FDA‑approved therapy is excluded from coverage.
    • Food challenge tests are covered once per suspected food allergen; additional challenges for the same food require authorization from an Independent Health Medical Director with specific clinical documentation.
    Dependence on maintenanceEfficacy typically requires ongoing or maintenance dosing to sustain increased threshold.